Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Warner Chilcott's Low-Dose FemHRT Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Company says low-dose FemHRT is "consistent" with hormone replacement therapy guidelines. The drug's second quarter launch could coincide with the introduction of Warner Chilcott's other recently approved hormone replacement therapy, Femtrace.

You may also be interested in...

Prempro Prescriptions On The Rise Thanks To DTC Campaign, Wyeth Says

Company sees a “small but consistent” increase in prescription volume and share for the hormone therapy, VP O’Connor says. Growth could indicate “swinging back of the pendulum” following two-year downturn resulting from the Women’s Health Initiative results.

Femtrace Launch Planned For Early 2005

Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.

Italy Leads European Push Into Conditional Reimbursement

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts